Insider buying last 90 days
No open-market insider purchases were filed for RLAY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RLAY insider filing, plotted on the chart in Gekko.Open RLAY in Gekko
NASDAQ: RLAY
Relay Therapeutics (RLAY) Stock Analysis & Forecast
Oct 12 close
$17.98+0.10 (+0.6%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on insider selling at Relay Therapeutics, with CEO Sanjiv Patel selling 48,199 shares at an average price of $18.10 for $872,401.90 under a 10b5-1 trading plan, followed by a proposed additional sale of 96,401 shares valued at $1,806,554.74. CFO Thomas Catinazzo also sold 17,717 shares worth $329,322. Separately, a comparison piece weighed RLAY against BioMarin Pharmaceutical on analyst recommendations, earnings and valuation, while another article framed the recent pullback as a test of the company's vascular anomalies valuation narrative, citing a fair value estimate of $27.58.
RLAY closed at $17.98, up 0.6%, sitting between its 50-day average of $19.04 and 200-day average of $14.31. The GekkoIndex reads 60.2, placing the stock in the Accumulation zone. The current price sits 19.9% below Gekko Fair Value of $22.44.
Relay Therapeutics next reports earnings on 5 November 2026 after close, 24 days away and inside a typical 20-trading-day holding window; the prior quarter's EPS of -0.41 matched estimates with a 0.4% reaction, against an average absolute reaction of 5.9%. Seasonality over the next 20 trading days has averaged -0.9% across 5 years, rising in 1 of them. One billionaire holder and one trailblazer holder are recorded, while insider, Congress and unusual options activity show no data in their respective windows.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Relay Therapeutics price vs fair value
Close $17.98200-day averageGekko Fair Value $22.44
Relay Therapeutics quick facts
- Market cap
- $3.94B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.56
- Revenue, TTM
- $10.35M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.73
- Volume
- 2.09M avg 3.40M
- 1-year return
- +165.2%
- Typical daily move
- ±5.8%
- Typical 20-day move
- ±13.6%
- 50-day average
- $19.04
- 200-day average
- $14.31
- Next earnings
- Nov 5 after close
- Shares outstanding
- 219.1M
Relay Therapeutics swing-trade checklist
Relay Therapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $17.98 sits between the 50-day ($19.04) and 200-day ($14.31) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.2, Accumulation
Reading 60.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
19.9% below
Price is 19.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.9% on average
From this point in the calendar, the next 20 trading days averaged −0.9% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Relay Therapeutics stock chart and price history
Relay Therapeutics closed at $17.98 on Oct 12, 2026, +165.2% over the past year, inside a 52-week range of $5.85 to $21.27.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.7%
- 3 months
- −5.8%
- 6 months
- +17.8%
- 1 year
- +165.2%
The full RLAY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RLAY in Gekko
Follow Relay Therapeutics through every session
Put RLAY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RLAY in GekkoFree for 7 days. No credit card required.
About Relay Therapeutics
Relay Therapeutics develops precision medicines through clinical research, working to improve how small molecule treatments are designed for certain cancers and genetic diseases. The company is working to advance several drug candidates, among them an oral FGFR2 inhibitor in early human testing for solid tumors with FGFR2 alterations, a program aimed at mutant PI3K-alpha, and an oral SHP2 inhibitor in Phase 1 testing for patients with advanced solid tumors.
The company's work relies on partnerships that extend its research and development capacity. It collaborates with D. E. Shaw Research, which applies computational modeling of protein movement to help identify and refine potential therapies, and it has an agreement with Genentech covering further development and eventual commercialization of its SHP2 inhibitor program.
Relay Therapeutics began in 2015 under the name Allostery before adopting its current name later that year, and it is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker RLAY.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- relaytx.com
Relay Therapeutics GekkoIndex: the smart money zone
Relay Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.2, in the Accumulation zone, up 5.2 points over five sessions.
60.2Accumulation
Up 5.2 points over five sessions, from the Neutral zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 53 | +1.6% | +4.3% | ||
| Accumulation (current zone) | 220 | +1.2% | +1.7% | ||
| Neutral | 365 | +0.3% | +5.4% | ||
| Distribution | 43 | +4.5% | +2.7% | ||
| Selling | 1 | Too few readings yet | |||
Average RLAY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the RLAY price, zone by zone.Track RLAY in Gekko
Is Relay Therapeutics stock overvalued? Gekko Fair Value
Relay Therapeutics trades 19.9% below Gekko Fair Value of $22.44, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Relay Therapeutics shares are worth, recalculated every trading day.
$22.44
Gekko Fair Value, Oct 10, 2026
19.9% Undervalued
At the end of Aug 2026 the price was 24.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open RLAY in Gekko
Relay Therapeutics insider and Congress trading
No open-market insider purchases were filed for Relay Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RLAY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RLAY, plotted on the chart in Gekko.Open RLAY in Gekko
Buybacks
Relay Therapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2025
- $653K
- As a share of market cap
- 0.02%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold RLAY.
0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Relay Therapeutics earnings: next date and track record
Relay Therapeutics reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- −$0.40
- Revenue estimate
- $1.62M
5 of 8reports beat the EPS estimate
±5.9%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.41 est −$0.41 | $350K est $960K | +0.4% |
| May 5, 2026 | −$0.41 est −$0.36 | $3.00M est $5.58M | −1.3% |
| Feb 26, 2026 | −$0.32 est −$0.41 | $7.00M est $4.97M | +11.3% |
| Nov 6, 2025 | −$0.43 est −$0.39 | — est $4.96M | −7.6% |
| Aug 7, 2025 | −$0.41 est −$0.49 | $677K est $14K | −8.8% |
| May 5, 2025 | −$0.46 est −$0.48 | $7.68M est $3.76M | −3.1% |
| Feb 26, 2025 | −$0.45 est −$0.55 | — est $5.53M | −11.7% |
| Nov 6, 2024 | −$0.63 est −$0.77 | — est $67K | +3.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Relay Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Relay Therapeutics is $27.58, +53.4% from the last close, from 9 firms rating the stock in the last 90 days.
$27.58consensus 12-month target, +53.4% from the last close
Now $17.98Avg $27.58
Low $20High $31
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | Bank of America Securities | $25 | +39.0% |
| Sep 27 | JonesTrading | $20 | +11.2% |
| Sep 22 | JonesTrading | $20 | +11.2% |
| Aug 20 | H.C. Wainwright | $29 | +61.3% |
| Aug 14 | J.P. Morgan | $31 | +72.4% |
+1.7%average 20-day move after past Accumulation readings
−0.9%average move over the next 20 trading days in the last 5 years
±5.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Relay Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Relay Therapeutics averaged −0.9% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.6% | 2 of 5 |
| Next 10 trading days | −5.6% | 2 of 5 |
| Next 15 trading days | −1.5% | 3 of 5 |
| Next 20 trading days | −0.9% | 1 of 5 |
| Next 30 trading days | −6.5% | 2 of 5 |
For scale, RLAY’s typical 20-trading-day move in either direction is about 13.6%.
Relay Therapeutics market cap and key statistics
Relay Therapeutics’s market cap is $3.94B and revenue of $10.35M over the last twelve months.
Valuation
- Market cap
- $3.94B
- EPS, TTM
- −$1.56
- Gekko Fair Value
- $22.44
Trading
- Volume
- 2.09M
- Avg volume, 20 days
- 3.40M
- 52-week high
- $21.27
- 52-week low
- $5.85
- Shares outstanding
- 219.1M
Financials
- Revenue, TTM
- $10.35M
- Profit margin
- 0%
- Return on equity
- -36.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.73
- Typical daily move
- ±5.8%
- Typical 20-day move
- ±13.6%
Relay Therapeutics stock news this week
Coverage of Relay Therapeutics this week reads neutral: 2 positive, 6 neutral and 4 negative headlines.
- Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)Defense World, Oct 12
- Form 144 RELAY THERAPEUTICS INC For: 11 October By Investing.comInvesting.com Nigeria, Oct 11
- Relay Therapeutics (NASDAQ:RLAY) CEO Sells $872,401.90 in StockDefense World, Oct 11
- Relay Therapeutics CEO Sanjiv Patel sells $872,401 company stockInvesting.com, Oct 9
- Relay Therapeutics CFO Catinazzo sells $329k in sharesInvesting.com, Oct 8
- Form 4 Relay Therapeutics Inc For: 8 October By Investing.comInvesting.com UK, Oct 8
Relay Therapeutics peers
Relay Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Relay Therapeutics stock FAQ
What is Relay Therapeutics’s market cap?
Relay Therapeutics’s market cap is $3.94B at the Oct 12, 2026 close of $17.98, with 219.1M shares outstanding.
What is the Relay Therapeutics stock forecast?
The consensus analyst 12-month price target for Relay Therapeutics is $27.58, +53.4% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Relay Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Relay Therapeutics is undervalued: the Oct 12, 2026 close of $17.98 is 19.9% below Gekko Fair Value of $22.44. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Relay Therapeutics report earnings next?
Relay Therapeutics is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of −$0.40 per share on revenue of $1.62M. Relay Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 5.9% on average across the report.
What is Relay Therapeutics’s 52-week high and low?
Relay Therapeutics’s 52-week high is $21.27 and its 52-week low is $5.85; it closed at $17.98 on Oct 12, 2026, +165.2% over the past year. Over the last five years the shares peaked at $37.67 on Oct 14, 2021.
Is Relay Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Relay Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.